Literature DB >> 12174118

Cutaneous embolization of cardiac myxoma.

M J García-F-Villalta1, T Sanz-Sánchez, M Aragüés, A Blasco, J Fraga, A García-Diez.   

Abstract

Atrial myxoma is the most common primary tumour of the heart. Skin manifestations in patients with a cardiac myxoma are frequent and may be due to cutaneous emboli, or may be specific findings as part of more complex syndromes. We present a 33-year-old-man with a history of episodes of pain in both legs and an ischaemic neurological event, who also had episodes of acral papular erythematous lesions on the legs and feet including the soles. The histological finding of dermal vessels occluded by a myxomatous material was the clue to the diagnosis of a cardiac myxoma. The diagnosis of this entity can be very difficult, because of the broad spectrum of clinical features; rarely the skin manifestations lead to the diagnosis of this tumour. The histological recognition of the myxomatous emboli is of vital importance for the diagnosis and treatment of this disease.

Entities:  

Mesh:

Year:  2002        PMID: 12174118     DOI: 10.1046/j.1365-2133.2002.04807.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Carney complex presenting with Raynaud's phenomenon and erythematous macules of the extremities.

Authors:  L J Mirkinson; K Ratnayaka; C A Sable; P R A Gaskin
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

2.  Nicolau syndrome following intramuscular diclofenac injection.

Authors:  Sillan Nayci; Mehmet S Gurel
Journal:  Indian Dermatol Online J       Date:  2013-04

3.  Nicolau syndrome as an avoidable complication.

Authors:  Engin Senel
Journal:  J Family Community Med       Date:  2012-01

Review 4.  Bar Code Reader - an algorithmic approach to cutaneous occluding vasculopathies? part II medium vessel vasculopathies.

Authors:  Gudrun Ratzinger; Bettina G Zelger; Bernhard W Zelger
Journal:  J Dtsch Dermatol Ges       Date:  2019-11       Impact factor: 5.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.